Karyopharm - oncology

Quote
CPA = professional designation
MBA = academic degree

I am not knocking anyone, but in terms of practical world use, I like the CPA better.

So I think the new CFO’s CPA complemented with a mini-MBA in biotechnology is credentialed enough to not knock her background.
 


















anonymous said:
CPA = professional designation
MBA = academic degree

I am not knocking anyone, but in terms of practical world use, I like the CPA better.

So I think the new CFO’s CPA complemented with a mini-MBA in biotechnology is credentialed enough to not knock her background.
Click to expand...
It’d be nice if she had a degree from a top tier school.
 












anonymous said:
CPA = professional designation
MBA = academic degree

I am not knocking anyone, but in terms of practical world use, I like the CPA better.

So I think the new CFO’s CPA complemented with a mini-MBA in biotechnology is credentialed enough to not knock her background.
Click to expand...
Is it considered a resume builder to join a company shortly before they file for bankruptcy to manage that process and the subsequent asset sale?
 
























anonymous said:
CPA is more professional, while MBA is more academic
Click to expand...
Perhaps, however it doesn't really matter at companies like ours as the CFO is merely window dressing and is mainly the conduit between our accounting firm, auditors and consultants. For instance Ernst & Young does the heavy lifting from the accounting perspective and the CFO translates the finance langue to the CEO, they present the E&Y findings on the earnings call, they call can speak to gross to net, inventory, spend, revenue, etc, however most of those decisions are offered up by the consultants...especially in our case as our CEO as no financial or banking background. What weak CEO's like ours wants in a CFO is a "Yes" man or women who will not challenge their thinking, question their ideas, or are ones who may be looking to take their job. That is what we just got ourselves...

Like any of this matters... with 115M outstanding shares, that are only going to get more diluted, there will not be much to manage. You could five to one split this and it will not hold.
 






anonymous said:
Perhaps, however it doesn't really matter at companies like ours as the CFO is merely window dressing and is mainly the conduit between our accounting firm, auditors and consultants. For instance Ernst & Young does the heavy lifting from the accounting perspective and the CFO translates the finance langue to the CEO, they present the E&Y findings on the earnings call, they call can speak to gross to net, inventory, spend, revenue, etc, however most of those decisions are offered up by the consultants...especially in our case as our CEO as no financial or banking background. What weak CEO's like ours wants in a CFO is a "Yes" man or women who will not challenge their thinking, question their ideas, or are ones who may be looking to take their job. That is what we just got ourselves...

Like any of this matters... with 115M outstanding shares, that are only going to get more diluted, there will not be much to manage. You could five to one split this and it will not hold.
Click to expand...
You used the words thinking and ideas when referring to r P. I think you’re stretching things a bit.
 
























Flatline.

”Based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $30 million for the fourth quarter 2024 and approximately $145 million for the full year 2024, and U.S. XPOVIO net product revenue to be approximately $29 million for the fourth quarter 2024 and approximately $113 million for the full year 2024.”
 






anonymous said:
Flatline.

”Based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $30 million for the fourth quarter 2024 and approximately $145 million for the full year 2024, and U.S. XPOVIO net product revenue to be approximately $29 million for the fourth quarter 2024 and approximately $113 million for the full year 2024.”
Click to expand...
Shares down over 7%. Market’s not impressed.
 






























Top Bottom
Back
Quote